Auriacombe, S., Pere, J. J., Loria-Kanza, Y. and Vellas, B. (2002). Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical Research and Opinion, 18, 129–138.
Bartorelli, L. et al. (2005). Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Current Medical Research and Opinion, 21, 1809–1818.
Bullock, R. and Connolly, C. (2002). Switching cholinesterase inhibitor therapy in Alzheimer's disease: donepezil to rivastigmine, is it worth it? International Journal of Geriatric Psychiatry, 17, 288–289.
Burns, A. et al. (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 20, 732–755.
Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J. J. and Bourdeix, I. (2006). Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice, 60, 110–118.
Darreh-Shori, T. et al. (2002). Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology, 59, 563–572.
Darvesh, S., Hopkins, D. A. and Geula, C. (2003). Neurobiology of butyrylcholinesterase. Nature Reviews Neurosciences, 4, 131–138.
Davidsson, P., Blennow, K., Andreasen, N., Eriksson, B., Minthon, L. and Hesse, C. (2001). Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscence Letters, 300, 157–160.
Dybicz, S. B., Keohane, D. J., Erwin, W. G., McRae, T. and Shah, S. N. (2006). Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. American Journal of Geriatric Pharamacotherapy, 4, 154–160.
Gardette, V. et al. (2010). Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs, 24, 431–442.
Gauthier, S., Juby, A., Morelli, L., Rehel, B. and Schecter, R. (2006). A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Current Medical Research and Opinion, 22, 2251–2265.
Herrmann, N. et al. (2007). A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society, 55, 1517–1523.
Herrmann, N., Binder, C., Dalziel, W., Smyth, S. and Camacho, F. (2009). Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs and Aging, 26, 403–407.
Hogan, D. B. et al. (2007). Management of mild to moderate Alzheimer's disease and dementia. Alzheimers and Dementia, 3, 355–384.
Jann, M. W., Shirley, K. L. and Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clinical Pharmacokinetics, 41, 719–739.
Massoud, F. and Gauthier, S. (2010). Update on the pharmacological treatment of Alzheimer's disease. Current Neuropharmacology, 8, 69–80.
Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481–488.
Mucha, L., Shaohung, S., Cuffel, B., McRae, T., Mark, T. L. and Del, V. M. (2008). Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. Journal of Managed Care Pharmacy, 14, 451–461.
Onor, M. L., Trevisiol, M. and Aguglia, E. (2007). Rivastigmine in the treatment of Alzheimer's disease: an update. Clinical Interventions in Aging, 2, 17–32.
Perry, E. K., Perry, R. H., Blessed, G. and Tomlinson, B. E. (1978). Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathology and Applied Neurobiology, 4, 273–277.
Robinson, D. M. and Plosker, G. L. (2006). Galantamine extended release in Alzheimer's disease: profile report. Drugs and Aging, 23, 839–842.
Rogers, S. L., Doody, R. S., Pratt, R. D. and Ieni, J. R. (2000). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a U.S. multicentre open-label study. European Neuropsychopharmacology, 10, 195–203.
Sadowsky, C. H. et al. (2005). Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Primary Care Companion to Journal of Clinical Psychiatry, 7, 43–48.
Sadowsky, C. H., Dengiz, A., Olin, J. T., Koumaras, B., Meng, X. and Brannan, S. (2009). Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 24, 267–275.
Seltzer, B. (2007). Donepezil: an update. Expert Opinion Pharmacotherapy, 8, 1011–1023.
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S. and Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317–324.
Wilkinson, D. G. and Howe, I. (2005). Switching from donepezil to galantamine: a double-blind study of two wash-out periods. International Journal of Geriatric Psychiatry, 20, 489–491.